Clinical and microbiologic characteristics of cephalosporin-resistant escherichia coli at three centers in the United States

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1870-1876

  Park, Yoon Soo ^a,b   Adams Haduch, Jennifer M ^a   Shutt, Kathleen A ^a   Yarabinec III, Daniel M ^a   Johnson, Laura E ^c   Hingwe, Ameet ^c   Lewis II, James S ^d   Jorgensen, James H ^d   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Gachon University College of Medicine   (South Korea)

^c Henry Ford Health System Division of Infectious Diseases   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; CEFEPIME; CEPHALOSPORIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BLADDER CATHETERIZATION; CARDIOVASCULAR DISEASE; CAUCASIAN; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HEALTH STATUS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNITED STATES;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINASE; DEMOGRAPHY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HEALTH STATUS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84863342359     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05650-11     Document Type: Article

References (18)

1. Bush K. 2008. Extended-spectrum β-lactamases in North America, 1987 to 2006. Clin. Microbiol. Infect. 14(Suppl. 1):134-143.
2. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing, 19th informational supplement. M100-S19. CSLI, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing, 20th informational supplement. M100-S20. CSLI, Wayne, PA.
4. Endimiani A, et al. 2008. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob. Agents Chemother. 52:2680-2682. (Pubitemid 351915709)
5. Friedman ND, et al. 2002. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann. Intern. Med. 137:791-797. (Pubitemid 35334450)
6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. 1988. CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control. 16: 128-140.
7. Jacoby GA. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161-182.
8. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51:286-294.
9. Lewis JS, II, Herrera M, Wickes B, Patterson JE, Jorgensen JH. 2007. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob. Agents Chemother. 51:4015-4021. (Pubitemid 350057800)
10. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553. (Pubitemid 36158080)
11. Paterson DL, Bonomo RA. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
12. Peirano G, Costello M, Pitout JD. 2010. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int. J. Antimicrob. Agents 36:19-23.
13. Pitout JD, Laupland KB. 2008. Extended-spectrum β-lactamase- producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8:159-166. (Pubitemid 351249250)
14. Poirel L, Gniadkowski M, Nordmann P. 2002. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J. Antimicrob. Chemother. 50:1031-1034. (Pubitemid 36049950)
15. Sidjabat HE, et al. 2009. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob. Agents Chemother. 53:4733-4739.
16. Sidjabat HE, et al. 2009. Clinical features and molecular epidemiology of CMY-type β-lactamase-producing Escherichia coli. Clin. Infect. Dis. 48:739-744.
17. Urban C, et al. 2010. Identification of CTX-M β-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn. Microbiol. Infect. Dis. 66:402-406.
18. Wang P, et al. 2011. Susceptibility of extended-spectrum-β- lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J. Clin. Microbiol. 49:3127-3131.